Xilio Therapeutics, INC

Xilio Therapeutics reported Q1 2026 financial results, highlighting pipeline progress with XTX501 and masked T cell engagers, and extended its cash runway into early 2028.

Xilio Therapeutics has appointed Dr. Cheryl Blanchard as a Class III director and chair of the Compensation Committee, succeeding the outgoing Christina Rossi.

Xilio Therapeutics announced its Q4 and full-year 2025 financial results, highlighting significant pipeline progress and an extended cash runway through 2027.

Xilio Therapeutics will implement a 1-for-14 reverse stock split to meet Nasdaq's minimum bid price requirement, effective March 13, 2026.

Xilio Therapeutics' stockholders have approved a reverse stock split of its common shares, with the exact ratio and timing at the board's discretion.

Xilio Therapeutics announced the pricing of an underwritten offering of pre-funded warrants to purchase 74.8 million common shares, expecting to raise approximately $37.1 million in net proceeds.

Xilio Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing increased collaboration revenue, higher R&D spending, and a strengthened cash position.

Xilio Therapeutics announced its Q3 2025 financial results, showing increased revenue from collaborations and extending its cash runway into Q1 2027, despite ongoing operating losses and a going concern doubt.

Xilio Therapeutics reported increased collaboration revenue and a significant capital raise, extending its cash runway through Q3 2026, despite ongoing operating losses and substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics reports Q1 2025 results, highlighting a new collaboration with AbbVie while acknowledging substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics' Q3 2024 report reveals ongoing losses and substantial doubt about its ability to continue as a going concern, despite a recent licensing deal with Gilead.

Xilio Therapeutics' Q2 2024 results show a net loss of $13.9 million and a license revenue of $2.4 million, while also expressing substantial doubt about its ability to continue as a going concern.

Xilio Therapeutics, a clinical-stage biotechnology company, reported a significant reduction in net losses for 2025, driven by increased collaboration revenue and strategic advancements in its immuno-oncology pipeline.

Xilio Therapeutics files its 2024 10-K, detailing clinical progress and strategic collaborations in its tumor-activated immuno-oncology pipeline.

Xilio Therapeutics reports its 2023 financial results, strategic portfolio reprioritization, workforce reduction, and an exclusive licensing agreement with Gilead for its IL-12 program.

Director Akintunde Olatokumbo Bello was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Director James Samuel Shannon was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity incentive.

Director Daniel J. Curran was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Director Xu Yuan was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of standard equity compensation.

Director Robert W. Ross was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of standard equity compensation.

Director Sara Bonstein was granted 5,000 stock options in Xilio Therapeutics, Inc. as part of a standard equity compensation arrangement.

Xilio Therapeutics has filed its 2026 proxy statement, seeking stockholder approval for director elections, auditor ratification, and an amendment to its 2021 Stock Incentive Plan.

Xilio Therapeutics, Inc. will hold a special meeting on February 23, 2026, for stockholders to vote on a reverse stock split to meet Nasdaq's minimum bid price requirement.

Xilio Therapeutics will hold a special meeting on November 21, 2025, to vote on repricing underwater employee stock options and approving a new 2025 Stock Incentive Plan to address significant dilution and retain talent.

Xilio Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $50.0 million underwritten public offering of pre-funded and common stock warrants to fund operations through Q3 2026.

Xilio Therapeutics is holding its 2025 Annual Meeting on June 10, 2025, seeking stockholder approval for key proposals including increasing authorized shares and officer exculpation.

Xilio Therapeutics is asking stockholders to approve increasing authorized common stock and providing officer exculpation at its 2025 annual meeting.

OrbiMed Advisors LLC and OrbiMed Capital GP X LLC have filed a Schedule 13G reporting a combined beneficial ownership of 9.99% in Xilio Therapeutics, Inc.

Bain Capital Life Sciences entities report a 9.99% beneficial ownership stake in Xilio Therapeutics, Inc. via pre-funded warrants.

Sirenia Capital Management LP and Alex Silverstein have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Xilio Therapeutics, Inc. common stock, primarily through exercisable warrants.

StemPoint Capital LP, along with its general partner and Michelle Ross, has disclosed an 8.4% beneficial ownership stake in Xilio Therapeutics, Inc., comprising common stock and warrants.

Frazier Life Sciences Public Fund and affiliated entities reported a combined beneficial ownership of 6.7% in Xilio Therapeutics, Inc. common stock as of December 31, 2025.

Gilead Sciences, Inc. has increased its beneficial ownership in Xilio Therapeutics, Inc. to 19.9% through a series of share issuances and pre-funded warrants.